Mouse Models of Parkinson Disease in the MICRON Literature

About the MICRON Research Literature

These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.

All publication counts and figures reflect the complete indexed research collection.

Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.

Understanding Parkinson Disease

Parkinson disease is a progressive neurodegenerative disorder characterized by degeneration of nigrostriatal dopaminergic neurons. Alpha-synuclein aggregates are a major pathological feature of most sporadic Parkinson disease but are not universal, particularly in some monogenic forms. In people the disease is identified by motor signs, bradykinesia with rigidity and rest tremor, that appear after years of antecedent change.

The retina carries a dopaminergic population of its own, a class of amacrine cells whose dopamine acts as a light-adaptation signal to the inner retina, so involvement of the eye in this disease is not simply a window onto the brain. Retinal dopamine is reported to be reduced in patients, and the deficits looked for, in contrast sensitivity, in color discrimination and in the electroretinogram, are what a loss of that local signal would predict.

Parkinson Disease in Experimental Research

What an animal model supplies turns on which half of the pathology it is built around:

• Toxin models, which lesion the dopaminergic system with MPTP or 6-hydroxydopamine, produce that loss rapidly and at a time the experimenter sets, rather than the synuclein aggregation
• Lines expressing human alpha-synuclein reproduce the aggregate pathology, and where the protein is tagged its deposition can be followed in the living retina, while their nigrostriatal cell loss and motor phenotype differ from line to line

What is harder to supply is the human diagnosis and part of the human ocular measurement. The diagnosis in people is clinical, based principally on the parkinsonian motor syndrome, with a clear response to dopaminergic therapy serving as an important supportive feature rather than a defining requirement. Contrast sensitivity has a behavioral counterpart in an animal that cannot report a threshold, but color discrimination along the axes used in patients does not, in a dichromat whose short-wavelength cone is shifted into the ultraviolet. Inner-retinal thinning is often assessed in macular ganglion-cell/inner-plexiform measures alongside peripapillary retinal-nerve-fiber-layer measures, and the macular measure needs a macula, which the mouse does not have.

Reduced contrast sensitivity and inner-retinal thinning are reported in other neurodegenerative diseases as well, so a retinal change in one of these models is evidence about the process that model carries and is not on its own specific to this disease.

Mouse Models of Parkinson Disease

The mouse carries most of this work.

Transgenic and knockout lines allow a pathway to be removed or overexpressed, and cost, availability, short generation time and a large body of background data reinforce the choice.

A genetic manipulation constrains rather than isolates a mechanism: developmental compensation and pleiotropy remain possible.

Published MICRON Research: Parkinson Disease in Mice

This page lists 3 papers from the MICRON literature, published 2016 to 2026, that study Parkinson disease in mice.

Of these publications:

• 3 studies used mice as the primary Parkinson disease disease model.

Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published Parkinson disease research.

Which imaging and experimental techniques are used in these studies?

Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.

Capabilities and Limitations of Imaging Techniques

A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.

Electroretinography

Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.

Optical Coherence Tomography

Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.

As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).

Optokinetic / Optomotor Response

Measures a reflexive head or eye movement tracking a moving pattern, giving a rapid, training-free behavioral estimate of spatial vision and contrast sensitivity in an animal that cannot report them. It is driven largely by reflex circuitry and reports on the visual pathway as a whole, so a deficit it detects still has to be localized by a structural or electrophysiological method, or separated from cortical processing by an operant task.

Topical Ophthalmic Drug Delivery

A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.

Which MICRON systems and add-ons appear?

Which strains and genetic lines are used?

What other conditions are recorded on the same papers?

Which MICRON configurations appear in this work?

Configurations recorded in these papers, and the techniques recorded alongside them.

The papers

Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.